OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gupta on Updated Data With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

February 16th 2025

Shilpa Gupta, MD, discusses updated data with enfortumab vedotin plus pembrolizumab in previously untreated urothelial carcinoma.

Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD

February 15th 2025

Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.

Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer

February 15th 2025

Dr Pothuri on the Current Treatment Paradigm in Endometrial Cancer

February 14th 2025

Bhavana Pothuri, MD, discusses the current treatment paradigm in endometrial cancer and the targeted therapies currently being investigated.

Dr Spencer on the Rationale of Evaluating a Novel CAR T-Cell Product in Pancreatic Cancer

February 14th 2025

Kristen Spencer, DO, details the rationale of the phase 1/2 EVEREST-2 trial evaluating the novel CAR T product A2B694 in pancreatic cancer.

Dr Albigès on Survival Outcomes With Cabozantinib Plus Nivolumab and Ipilimumab in RCC

February 14th 2025

Laurence Albigès, MD, PhD discusses final OS data and biomarker analyses with cabozantinib plus nivolumab and ipilimumab in intermediate- or poor-risk RCC.

Joseph on the Effects of Resistance Training on Fatigue and Pain in Multiple Myeloma

February 14th 2025

Janine Joseph, MS, MBA, discusses the effects of resistance training interventions on fatigue and pain levels in patients with multiple myeloma.

Dr Shah on Efficacy Data for Zamto-Cel in R/R DLBCL

February 14th 2025

Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma

Dr Dholaria on the Safety and Efficacy of P-BCMA-ALLO1 in R/R Myeloma

February 14th 2025

Dr Dholaria discusses the phase 1 trial of P-BCMA-ALLO1, highlighting high response rates, rapid CAR T-cell expansion, and a favorable safety profile in RRMM.

Dr Ahmed on NKTR-255 With CD19-Directed CAR T-Cell Therapy in R/R LBCL

February 14th 2025

Sairah Ahmed, MD, discusses evaluating NKTR-255 in combination with CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.

Dr Sabari on Considerations for Conducting and Interpreting HER2 Testing in NSCLC

February 14th 2025

Joshua K. Sabari, MD, discusses key considerations when testing for HER2 alterations in non–small cell lung cancer

Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer

February 14th 2025

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Dr Saad on the Efficacy of Darolutamide Plus ADT In Low and High Volume mHSPC

February 14th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.

Dr Wagar on the Role of Adjuvant Immunotherapy in Endometrial Cancer

February 13th 2025

Matthew Wagar, MD, discusses the use of adjuvant immunotherapy in endometrial cancer and the importance of accurate staging in optimizing outcomes.

Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

February 13th 2025

The MANIFEST-2 trial showed that pelabresib/ruxolitinib led to greater spleen volume reduction and improved anemia vs ruxolitinib alone in myelofibrosis

Dr Ahluwalia on the Evolution of Precision Medicine in Oncology

February 13th 2025

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses oncology advances that were highlighted at the Miami Cancer Institute Precision Oncology Symposium.

Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases

February 13th 2025

Kelly E. McCann, MD, PhD, discusses current and evolving treatment strategies for patients with HER2-positive breast cancer who develop brain metastases.

Dr Sullivan on RP1 Plus Nivolumab in Anti–PD-1–Refractory Melanoma

February 12th 2025

Ryan Sullivan, MD, discusses RP1 plus nivolumab in patients with advanced melanoma who progressed on prior anti–PD-1 therapy.

Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas

February 12th 2025

Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm.

Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma

February 12th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses considerations in selecting frontline therapy for patients with metastatic melanoma.